BRIEF-Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology

Reuters01-20

BRIEF-<a href="https://laohu8.com/S/ILMN">Illumina</a> Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology

Jan 20 (Reuters) - Illumina Inc ILMN.O:

ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT™ ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGY
ILLUMINA INC - FDA-APPROVED TEST REIMBURSED AT $2,989.55 PER TEST

Source text: ID:nPn92JJYFa

Further company coverage: ILMN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604811944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604811944","market":"fut","top_or_hot":-1,"title":"BRIEF-Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology</title></head><body><p><span>Jan 20 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a> <span>ILMN.O</span>:</p><ul><li><p>ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT™ ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGY</p></li><li><p>ILLUMINA INC - FDA-APPROVED TEST REIMBURSED AT $2,989.55 PER TEST</p></li></ul><p>Source text: <span>ID:nPn92JJYFa</span></p><p>Further company coverage: <span>ILMN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-20 22:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ILMN\">Illumina</a> Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology</title></head><body><p><span>Jan 20 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ILMNV\">Illumina Inc</a> <span>ILMN.O</span>:</p><ul><li><p>ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT™ ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGY</p></li><li><p>ILLUMINA INC - FDA-APPROVED TEST REIMBURSED AT $2,989.55 PER TEST</p></li></ul><p>Source text: <span>ID:nPn92JJYFa</span></p><p>Further company coverage: <span>ILMN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA8DYDGF:1","article_id":"2604811944","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604811944","pubTimestamp":1768918729,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision OncologyJan 20 (Reuters) - Illumina Inc ILMN.O:ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIG","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","ILMN":"Illumina","BK4121":"生命科学工具和服务","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Illumina为TruSight Oncology Comprehensive获得CMS报销，扩大精准肿瘤学的覆盖范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":0.9},"content_text":"BRIEF-Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision OncologyJan 20 (Reuters) - Illumina Inc ILMN.O:ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT™ ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGYILLUMINA INC - FDA-APPROVED TEST REIMBURSED AT $2,989.55 PER TESTSource text: ID:nPn92JJYFaFurther company coverage: ILMN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604811944","isCrawlerRequest":true}